Systematic Review of Antiretroviral Treatments for Chronic Hepatitis B (CHB)

Bristol-Myers Squibb100 enrolled

Overview

The purpose of this study is to support the clinical value of entecavir by assessing the relationship between viral load and histological improvement.

Systematic review of prospective clinical trials

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Hepatitis B, Chronic

Eligibility

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with CHB diagnosis and no co-infection with Hep A, Hep C, Hep D, or HIV * Age 16 years or older * No post-transplant patients * RCT, non-randomized trials, prospective cohort studies, prospectively analyses case series published since 2003 * At least one arm of trial must include monotherapy with entecavir, lamivudine, tenofovir, adefovir, or telbivudine * Study arms must include at least 10 patients * Follow-up of at least 48 weeks * Published results available in English language Exclusion Criteria: * N/A

Outcomes

Primary Outcomes

Viral load

Histological improvement

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.